Arno Therapeutics, Inc. (Arnothera)

Oncology Corporate Profile

HQ Location

200 Route 31 North, Suite 104
Flemington, NJ 08822

Company Description

Arno Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes innovative products for the treatment of cancer patients. Arno's lead clinical compound, AR-67 is a novel, third-generation camptothecin analogue that inhibits Topoisomerase I activity.

Website: http://www.arnothera.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
onapristoneanti-progestinProstate cancerII
AR-42Pan-DAC/AKT pathway inhibitorVarious cancer typesI
AR-12PI3-k/AKT pathway inhibitorVarious cancer typesI
onapristoneanti-progestinVarious cancer typesI

View additional information on product candidates here »

Pipeline image

Source


http://www.arnothera.com

Recent News Headlines

CU Cancer Center’s Paul Bunn, Jr., MD, FASCO, Earns ASCO David A. Karnofsky Memorial Award

6/2/2016 12:03 pm

(UCCC/Colorado Cancer Blogs) June 2, 2016 - Paul Bunn, Jr., MD, FASCO, distinguished professor at the University of Colorado Cancer Center and James Dudley Professor of Lung Cancer Research at the University of Colorado School of Medicine has been named the 2016 David A. Karnofsky Memorial Award and Lecture recipient, a prestigious award presented at the American Society of Clinical Oncology’s (ASCO) Annual Meeting.

Arno Therapeutics Advances Phase I/II Trial Evaluating Onapristone in Prostate Cancer to Phase II

3/21/2016 11:33 am

(OTC Markets) Mar 21, 2016 - Arno Therapeutics, Inc. today announced that it has enrolled the first patient in the second stage of its Phase I/II clinical trial evaluating onapristone in men with advanced castration-resistant prostate cancer (CRPC), after failure of abiraterone or enzalutamide.

Merck: A Leg Up In The Cancer Drug Race

2/4/2016 12:02 pm

(Wall Street Journal/MoneyBeat blog) Feb 3, 2016 - Highly anticipated results from a phase 3 clinical trial of Keytruda as a single therapy in a form of lung cancer will be available in the middle of the year.

Arno Therapeutics Receives Authorization to Proceed With Modified Phase I/II Trial Evaluating Onapristone in Prostate Cancer

8/18/2015 12:16 pm

(TheStreet) Aug 18, 2015 - Arno Therapeutics, Inc. today announced that it has received authorization from the Medicines and Healthcare products Regulatory Authority (MHRA) to begin enrolling patients in the United Kingdom in the second stage of its Phase I/II clinical trial evaluating lead compound onapristone in men with advanced castration-resistant prostate cancer (CRPC).

Clovis Wins One ASCO '15 Battle, Loses Another, Against Rival AstraZeneca

6/1/2015 06:00 pm

(TheStreet) June 1, 2015 - Clovis and AstraZeneca are developing competing therapies against lung and ovarian cancer.

Arno Therapeutics Announces Data Validating Continued Onapristone and Companion Diagnostic Development at ASCO Annual Meeting 2015

5/14/2015 01:24 pm

(TheStreet) May 13, 2015 - Arno Therapeutics, Inc., a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer and other life threatening diseases, today announced promising data supporting the ongoing clinical development program for lead compound onapristone to be presented at the upcoming 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 29-June 2 in Chicago, IL.

Arno Therapeutics Doses First Patient in Expansion Stage of Modified Phase I/II Trial Evaluating Onapristone in Progesterone Receptor Positive Tumors

12/10/2014 02:42 pm

(Yahoo! Finance) Dec 10, 2014 - Study in APR positive endometrioid cancer patients.

FDA Advisors: No to Nebivolol/Valsartan Combo Pill for HTN

9/10/2014 07:05 am

(Medscape Medical News) Sept 10, 2014 - An FDA advisory panel has recommended by a six-to-four vote that a dual-agent medication combining a beta-blocker and an angiotensin-receptor blocker (ARB) not be approved for the treatment of hypertension.

Yale Cancer Center Researchers Identify Possible Target for Immunotherapy in Early-Stage Breast Cancer

7/21/2014 06:00 am

(Yale Cancer Center) July 17, 2014 – Yale Cancer Center researchers used a new molecular analysis tool to accurately detect the level of an important target for immunotherapy in early-stage breast cancers.

Arno Therapeutics to Outline Two Phase I Studies Evaluating Onapristone in Men's and Women's Cancers at 2014 ASCO Annual Meeting

5/15/2014 02:20 pm

(NASDAQ) May 14, 2014 - Arno Therapeutics, Inc. today announced two, separate abstracts outlining the study designs of ongoing Phase I clinical trials evaluating its investigational lead compound onapristone to be presented at ASCO.

Arno Therapeutics to Outline Two Phase I Studies Evaluating Onapristone in Men's and Women's Cancers at 2014 ASCO Annual Meeting

5/15/2014 09:02 am

(NASDAQ) May 14, 2014 - Arno Therapeutics, Inc. today announced two, separate abstracts outlining the study designs of ongoing Phase I clinical trials evaluating its investigational lead compound onapristone to be presented at ASCO.

Arno Therapeutics Enrolls First Patient in a Phase I/II Trial Evaluating Onapristone in Men with Advanced Castration-Resistant Prostate Cancer

4/7/2014 02:32 pm

(Arno Therapeutics) Apr 7, 2014 - Arno Therapeutics, Inc. today announced that it has enrolled the first patient in a Phase I/II trial (NCT02049190) evaluating its lead compound onapristone in men with advanced castration-resistant prostate cancer (CRPC) after failure of abiraterone or enzalutamide.

Arno Therapeutics Enrolls First Patient in a Phase I/II Trial Evaluating Onapristone in Men with Advanced Castration-Resistant Prostate Cancer

4/7/2014 02:03 pm

(Arno Therapeutics) Apr 7, 2014 - Arno Therapeutics, Inc. today announced that it has enrolled the first patient in a Phase I/II trial (NCT02049190) evaluating its lead compound onapristone in men with advanced castration-resistant prostate cancer (CRPC) after failure of abiraterone or enzalutamide.

Arno Therapeutics Enrolls First Patient in a Phase I/II Trial Evaluating Onapristone in Men with Advanced Castration-Resistant Prostate Cancer

4/7/2014 12:47 pm

(Arno Therapeutics) Apr 7, 2014 - Arno Therapeutics, Inc. today announced that it has enrolled the first patient in a Phase I/II trial (NCT02049190) evaluating its lead compound onapristone in men with advanced castration-resistant prostate cancer (CRPC) after failure of abiraterone or enzalutamide.

Arno Therapeutics Enrolls First Patient in a Phase I Trial to Evaluate Lead Compound Onapristone in Progesterone Receptor Positive Solid Tumors

1/21/2014 12:17 pm

(MarketWatch) Jan 21, 2014 - Arno Therapeutics, Inc. today announced that it has enrolled the first patient in a Phase I dose escalation study evaluating onapristone in post-menopausal women with progesterone receptor (PR) positive tumors, including breast, endometrial and other solid tumors.

Arno Therapeutics Enrolls First Patient in a Phase I Trial to Evaluate Lead Compound Onapristone in Progesterone Receptor Positive Solid Tumors

1/21/2014 12:01 pm

(MarketWatch) Jan 21, 2014 - Arno Therapeutics, Inc. today announced that it has enrolled the first patient in a Phase I dose escalation study evaluating onapristone in post-menopausal women with progesterone receptor (PR) positive tumors, including breast, endometrial and other solid tumors.

Quest Introduces Breast-Cancer Gene Test Rivaling Myriad

10/15/2013 11:05 am

(Bloomberg) Oct 15, 2013 - Quest Diagnostics Inc., the biggest U.S. operator of medical labs, will sell a test for two breast cancer genes starting today, providing competition for Myriad Genetics Inc. and potentially helping to reduce costs for women fearful they are at risk of the disease.

UPMC-Highmark Feud Metastasizes in Westmoreland Cancer Center Billing Dispute

9/13/2013 11:02 am

(Tribune-Review [Pittsburgh, PA]) Sep 13, 2013 - The feud between Highmark and UPMC has spilled over to Westmoreland County's Arnold Palmer Cancer Pavilion — a joint UPMC-Excela Health venture — where officials say Highmark is refusing to pay reimbursements for chemotherapy treatments.

New ASCO/AAHPM Project Will Harness Technology to Foster Improved Palliative Care in Oncology

3/7/2013 12:01 pm

(ASCO in Action) Mar 6, 2013 - ASCO and the American Academy of Hospice and Palliative Care Medicine (AAHPM) today announced a joint initiative to support delivery of high-quality palliative care in medical oncology.

Bristol-Myers to Hold Talks on Settling Claims of Hepatitis C Patients

1/16/2013 12:03 pm

(Wall Street Journal) Jan 15, 2013 - Bristol-Myers is scheduled to hold talks to settle hundreds of millions of dollars in claims of liver-disease patients killed or injured during a company-sponsored drug trial last year.

GE Healthcare Launches 'Give a Little Beat' for Cancer Patients

10/19/2012 12:04 pm

(The Business Journal) Oct 18, 2012 - GE Healthcare is launching an initiative to connect people in the fight against breast cancer through the power of music and social media.

US FDA Rejects Merck/Ariad Sarcoma Drug

6/5/2012 04:02 pm

(Reuters) June 5, 2012 - U.S. drugs regulators rejected an experimental sarcoma medicine from Merck and Ariad Pharmaceuticals on Tuesday, asking for more clinical trials, Merck said.